Current status and advances of combination therapy for chronic hepatitis B

Chronic hepatitis B (CHB) is still a global public health problem, resulting in the high risk of decompensated cirrhosis and hepatocellular carcinoma. At present, there are no single available medications that can induce both potent HBV DNA suppression, and high rates of HBeAg and HBsAg clearance. Therefore, there is great interest in developing combination therapies for patients with chronic HBV infection, which can achieve sustained viral suppression and HBsAg negative inversion after a finite course of treatment leading to clinical cure. This article reviews the current status and advances of combination therapy for CHB. Key words: Chronic hepatitis B; Combination therapy; HBsAg clearance; clinical cure